These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22231566)

  • 1. Clinical and economic challenges facing pharmacogenomics.
    Cohen J; Wilson A; Manzolillo K
    Pharmacogenomics J; 2013 Aug; 13(4):378-88. PubMed ID: 22231566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming regulatory and economic challenges facing pharmacogenomics.
    Cohen JP
    N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Medicine's Bottleneck: Diagnostic Test Evidence and Reimbursement.
    Cohen JP; Felix AE
    J Pers Med; 2014 Apr; 4(2):163-75. PubMed ID: 25563222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Personalized Medicine Coalition: goals and strategies.
    Abrahams E; Ginsburg GS; Silver M
    Am J Pharmacogenomics; 2005; 5(6):345-55. PubMed ID: 16336000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New challenges to medicare beneficiary access to mAbs.
    Cohen J; Wilson A
    MAbs; 2009; 1(1):56-66. PubMed ID: 20046575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
    Cowling T; Boucher M
    Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARC report: health outcomes and value of personalized medicine interventions: impact on patient care.
    Mitropoulou C; Litinski V; Kabakchiev B; Rogers S; P Patrinos G
    Pharmacogenomics; 2020 Jul; 21(11):797-807. PubMed ID: 32635813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics.
    Trusheim MR; Berndt ER
    Drug Discov Today; 2015 Dec; 20(12):1439-50. PubMed ID: 26542060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inaugural Pharmacogenomics Access and Reimbursement Symposium.
    Rogers SL; Patrinos GP; Mitropoulou C; Formea CM; Jones JS; Brown BG
    Pharmacogenomics; 2021 Jun; 22(9):515-517. PubMed ID: 34032472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do companion diagnostics make economic sense for drug developers?
    Agarwal A
    N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacogenomics].
    Nakatani K; Nobori T
    Rinsho Byori; 2013 Nov; 61(11):1018-25. PubMed ID: 24450107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics: the promise of personalized medicine for CNS disorders.
    de Leon J
    Neuropsychopharmacology; 2009 Jan; 34(1):159-72. PubMed ID: 18800072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Payer view of personalized medicine.
    Pezalla EJ
    Am J Health Syst Pharm; 2016 Dec; 73(23):2007-2012. PubMed ID: 27864208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current and future state of companion diagnostics.
    Agarwal A; Ressler D; Snyder G
    Pharmgenomics Pers Med; 2015; 8():99-110. PubMed ID: 25897259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
    Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
    Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third Santorini conference pharmacogenomics workshop report: "Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?".
    Llerena A; Michel G; Jeannesson E; Wong S; Manolopoulos VG; Hockett RD; Boubekeur K; Siest G; Beaune P; Haefliger C; Arnold HP; Junien C; Petrovic N; Molloy R; Bekers O; Donnelly C; Arens HJ; Kaput J; McComb J
    Clin Chem Lab Med; 2007; 45(7):843-50. PubMed ID: 17617025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using companion and coupled diagnostics within strategy to personalize targeted medicines.
    Singer DR; Watkins J
    Per Med; 2012 Sep; 9(7):751-761. PubMed ID: 29776269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.